{"disease":{"id":"chronic-myeloid-leukemia-chronic-phase","name":"chronic myeloid leukemia chronic phase"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03509896","title":"Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)","phase":"","overall_status":"COMPLETED","enrollment_count":463,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT03722420","title":"Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":238,"lead_sponsor_name":"Il-Yang Pharm. Co., Ltd.","has_results":false},{"nct_id":"NCT04677439","title":"Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Shenzhen Second People's Hospital","has_results":false},{"nct_id":"NCT07375355","title":"Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06163430","title":"A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Terns, Inc.","has_results":false},{"nct_id":"NCT03454503","title":"Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt","phase":"","overall_status":"COMPLETED","enrollment_count":173,"lead_sponsor_name":"Hikma Pharmaceuticals LLC","has_results":false},{"nct_id":"NCT03459534","title":"A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":173,"lead_sponsor_name":"Il-Yang Pharm. Co., Ltd.","has_results":false},{"nct_id":"NCT03481868","title":"EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors","phase":"NA","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"University Hospital, Clermont-Ferrand","has_results":false},{"nct_id":"NCT04126681","title":"A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":144,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT04933526","title":"The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":118,"lead_sponsor_name":"Shenzhen Second People's Hospital","has_results":false},{"nct_id":"NCT06516029","title":"Real-World Evaluation of Patient Characteristics and Treatment Patterns Among Patients With CML-CP Treated With Asciminib","phase":"","overall_status":"COMPLETED","enrollment_count":111,"lead_sponsor_name":"Novartis","has_results":false},{"nct_id":"NCT03332511","title":"Efficacy and Safety of Nilotinib in CML-CP","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":110,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT02506933","title":"Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":102,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT03933852","title":"Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any Dose","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"University of Jena","has_results":false},{"nct_id":"NCT06119269","title":"Ponatinib in Chronic Myeloid Leukemia Patients in Chronic Phase","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"University of Pisa","has_results":false},{"nct_id":"NCT03942094","title":"Nilotinib for First-line Newly Diagnosed CML-CP Patients","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Shenzhen Second People's Hospital","has_results":false},{"nct_id":"NCT02727803","title":"Personalized NK Cell Therapy in CBT","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01529827","title":"Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT06427811","title":"Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":85,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03934372","title":"Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Incyte Biosciences International Sàrl","has_results":false},{"nct_id":"NCT06368414","title":"A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":69,"lead_sponsor_name":"Korean Society of Hematology","has_results":false},{"nct_id":"NCT00856388","title":"Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders","phase":"NA","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT02396134","title":"Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT06233890","title":"The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Imperial College Healthcare NHS Trust","has_results":false},{"nct_id":"NCT00795769","title":"Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT07020533","title":"A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":46,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT03885830","title":"Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients","phase":"","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03862157","title":"Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05311943","title":"Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Shenzhen Second People's Hospital","has_results":false},{"nct_id":"NCT05376852","title":"Decitabine and HQP1351-based Chemotherapy Regimen for the Treatment Advanced CML","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT01588015","title":"Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT03333486","title":"Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT00451035","title":"Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":29,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02398825","title":"Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"Gruppo Italiano Malattie EMatologiche dell'Adulto","has_results":false},{"nct_id":"NCT03882281","title":"Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT03079505","title":"Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Hamad Medical Corporation","has_results":false},{"nct_id":"NCT04060277","title":"Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":7,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT01914484","title":"Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT03878524","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT04006847","title":"Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Milton S. Hershey Medical Center","has_results":true},{"nct_id":"NCT04360005","title":"Managed Access Programs for ABL001, Asciminib","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false}],"total":41},"guidelines":[],"source":"Drug Landscape verified database"}